6 үр дүн
SUMMARY OF THE INVENTION
The compounds of the present invention are antagonists of the VLA-4 integrin ("very late antigen-4"; CD49d/CD29; or .alpha..sub.4.beta..sub.1), the .alpha..sub.4.beta..sub.7 integrin (LPAM-1 and .alpha..sub.4.beta..sub.p), and/or the .alpha..sub.9.beta..sub.1 integrin, and
This invention relates to novel benzoquinone derivatives having inhibitory activities of protocollagen proline hydroxylase, collagen biosynthesis and 5-lipoxygenase.
Protocollagen proline hydroxylase is an enzyme which specifically hydroxylates the proline residues of the protocollagen synthesized
This invention relates to novel benzoquinone derivatives having inhibitory activities of protocollagenproline hydroxylase, collagen biosynthesis and 5-lipoxygenase.
Protocollagen proline hydroxylase is an enzyme which specifically hydroxylates the proline residues of the protocollagen synthesized by
This invention relates to novel benzoquinone derivatives having inhibitory activities of protocollagenproline hydroxylase, collagen biosynthesis and 5-lipoxygenase.
Protocollagen proline hydroxylase is an enzyme which specifically hydroxylates the proline residues of the protocollagen synthesized by
This invention relates to novel benzoquinone derivatives having inhibitory activities of protocollagen proline hydroxylase, collagen biosynthesis and 5-lipoxygenase.
Protocollagen proline hydroxylase is an enzyme which specifically hydroxylates the proline residues of the protocollagen synthesized
This invention relates to novel benzoquinone derivatives having inhibitory activities of protocollagen-proline hydroxylase, collagen biosynthesis and 5-lipoxygenase.
Protocollagen proline hydroxylase is an enzyme which specifically hydroxylates the proline residues of the protocollagen synthesized